The Shanghai Municipal People’s Government has released the “Action Plan for Supporting Mergers and Acquisitions (M&A) of Listed Companies in Shanghai (2025-2027)”, which includes an allocation of an RMB 10 billion (USD 1.38 billion) fund specifically for M&A activities in the biopharmaceutical industry.
Strategic M&A Targets and Global Competitiveness
The document outlines a strategic goal to implement a series of representative M&A cases in key industries by 2027, with the aim of cultivating 10 listed companies that possess global competitiveness in sectors such as integrated circuits, biomedicine, and new materials. These M&A deals are projected to reach a total value of RMB 300 billion (USD 41.32 billion), which is expected to activate total assets exceeding RMB 2 trillion (USD 275.48 billion).
Enhancing Industry Growth and Investment
The M&A initiatives outlined in the action plan are designed to not only boost the competitiveness of Shanghai’s listed companies but also to stimulate significant growth and investment within the biopharmaceutical industry. The planned activities aim to create a more dynamic and robust market environment, attracting further investment and fostering innovation in the sector.-Fineline Info & Tech
